Amgen’s Neulasta gains another biosimilar competitor as sales slip

Neulasta, one of Amgen’s oldest drug franchises, has another biosimilar to contend with.

German pharma Fresenius Kabi announced on Tuesday that the FDA has approved its pegfilgrastim biosimilar, to be marketed as Stimufend. The drug will add to a growing arsenal of biosimilars used to treat neutropenia, a condition common...

Click to view original post